Dr Bahram Valamehr speaks to ecancer at the 2019 ASH meeting in Orlando about the first, novel CAR-NK agent to treat B cell malignancies.
He explains the process in creating this novel agent called FT596, which is available as an off-the-shelf product.
Dr Valamehr describes the next steps for this agent, including the establishment of a large clinical trial, which aims to assess the safety and efficacy of FT596 in patients.
He concludes by outlining the main advantages of this agent.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.
Watch the press conference here.
Read more about the study here.